CAM
XBI icon

Crestone Asset Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Crestone Asset Management’s Portfolio XBI Stock Details XBI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-3,224
Closed -$288K – 117
2023
Q4 		$288K Sell
3,224
-6,040
-65% -$449K 0.07% 75
2023
Q3 		$676K Sell
9,264
-5,651
-38% -$451K 0.16% 50
2023
Q2 		$1.24M Sell
14,915
-52
-0.3% -$4.35K 0.27% 47
2023
Q1 		$1.14M Sell
14,967
-6,708
-31% -$557K 0.24% 46
2022
Q4 		$1.8M Sell
21,675
-12,066
-36% -$977K 0.38% 36
2022
Q3 		$2.68M Sell
33,741
-47,722
-59% -$4.02M 0.68% 29
2022
Q2 		$6.05M Buy
81,463
+10,846
+15% +$814K 1.42% 19
2022
Q1 		$6.35M Buy
70,617
+62,845
+809% +$5.8M 1.33% 21
2021
Q4 		$870K Sell
7,772
-1,236
-14% -$149K 0.18% 46
2021
Q3 		$1.13M Sell
9,008
-2,377
-21% -$306K 0.25% 43
2021
Q2 		$1.54M Sell
11,385
-4,763
-29% -$626K 0.33% 37
2021
Q1 		$2.19M Sell
16,148
-305
-2% -$45.7K 0.57% 25
2020
Q4 		$2.32M Sell
16,453
-6,479
-28% -$830K 0.62% 26
2020
Q3 		$2.56M Sell
22,932
-8,438
-27% -$946K 0.8% 25
2020
Q2 		$3.51M Sell
31,370
-21,560
-41% -$2.12M 1.16% 22
2020
Q1 		$4.1M Sell
52,930
-3,527
-6% -$312K 1.67% 16
2019
Q4 		$5.37M Sell
56,457
-1,137
-2% -$98.3K 1.82% 17
2019
Q3 		$4.39M Buy
57,594
+2,674
+5% +$222K 1.67% 18
2019
Q2 		$4.82M Buy
54,920
+19,254
+54% +$1.64M 1.69% 17
2019
Q1 		$3.23M Buy
35,666
+4,986
+16% +$424K 1.14% 23
2018
Q4 		$2.2M Sell
30,680
-165
-0.5% -$13.3K 0.83% 25
2018
Q3 		$2.96M Buy
30,845
+19,634
+175% +$1.9M 1.3% 17
2018
Q2 		$1.07M Buy
+11,211
New +$1.03M 0.47% 26

Other funds holding XBI

Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Crestone Asset Management's XBI Position: Q1 2024 in Review

Crestone Asset Management sold out of State Street SPDR S&P Biotech ETF (XBI) in Q1 2024, closing a stake of 3,224 shares — an estimated $288K sold.

Crestone Asset Management first reported a position in XBI in Q2 2018 and held it in 23 quarters. The position peaked at $6.35M in Q1 2022. 780 funds tracked by Wall St. Rank hold XBI as of Q1 2024.

  • Crestone Asset Management reported no remaining State Street SPDR S&P Biotech ETF position as of Q1 2024 after selling out during the quarter.
  • Crestone Asset Management sold 3,224 State Street SPDR S&P Biotech ETF shares in Q1 2024, an estimated $288K.
  • Crestone Asset Management first reported a position in State Street SPDR S&P Biotech ETF in Q2 2018 and held it in 23 quarters.
  • Crestone Asset Management's State Street SPDR S&P Biotech ETF position peaked at $6.35M in Q1 2022.
  • 780 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2024.

Based on Crestone Asset Management's 13F filing for Q1 2024, filed 26 Apr 2024.